Logo image of SPRY

ARS PHARMACEUTICALS INC (SPRY) Stock Fundamental Analysis

NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD

15.49  +0.64 (+4.31%)

After market: 15.49 0 (0%)

Fundamental Rating

4

Overall SPRY gets a fundamental rating of 4 out of 10. We evaluated SPRY against 560 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SPRY as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, SPRY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SPRY has reported negative net income.
SPRY had a negative operating cash flow in the past year.
SPRY had negative earnings in 4 of the past 5 years.
SPRY had negative operating cash flow in 4 of the past 5 years.
SPRY Yearly Net Income VS EBIT VS OCF VS FCFSPRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -4.78%, SPRY belongs to the top of the industry, outperforming 87.86% of the companies in the same industry.
SPRY has a Return On Equity of -6.83%. This is amongst the best in the industry. SPRY outperforms 89.11% of its industry peers.
Industry RankSector Rank
ROA -4.78%
ROE -6.83%
ROIC N/A
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
SPRY Yearly ROA, ROE, ROICSPRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

SPRY has a better Gross Margin (90.89%) than 92.86% of its industry peers.
The Profit Margin and Operating Margin are not available for SPRY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 90.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRY Yearly Profit, Operating, Gross MarginsSPRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

8

2. Health

2.1 Basic Checks

SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
SPRY has more shares outstanding than it did 1 year ago.
SPRY has more shares outstanding than it did 5 years ago.
SPRY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SPRY Yearly Shares OutstandingSPRY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SPRY Yearly Total Debt VS Total AssetsSPRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SPRY has an Altman-Z score of 9.65. This indicates that SPRY is financially healthy and has little risk of bankruptcy at the moment.
SPRY has a better Altman-Z score (9.65) than 87.86% of its industry peers.
There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.65
ROIC/WACCN/A
WACC9.53%
SPRY Yearly LT Debt VS Equity VS FCFSPRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

SPRY has a Current Ratio of 11.00. This indicates that SPRY is financially healthy and has no problem in meeting its short term obligations.
SPRY's Current ratio of 11.00 is amongst the best of the industry. SPRY outperforms 81.43% of its industry peers.
A Quick Ratio of 10.74 indicates that SPRY has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.74, SPRY belongs to the top of the industry, outperforming 80.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 11
Quick Ratio 10.74
SPRY Yearly Current Assets VS Current LiabilitesSPRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.46% over the past year.
The Revenue has grown by 971120.00% in the past year. This is a very strong growth!
EPS 1Y (TTM)63.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
Revenue 1Y (TTM)971120%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SPRY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 88.12% yearly.
The Revenue is expected to grow by 104.65% on average over the next years. This is a very strong growth
EPS Next Y-2966.2%
EPS Next 2Y-269.16%
EPS Next 3Y67.41%
EPS Next 5Y88.12%
Revenue Next Year380.02%
Revenue Next 2Y240.61%
Revenue Next 3Y163.51%
Revenue Next 5Y104.65%

3.3 Evolution

SPRY Yearly Revenue VS EstimatesSPRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SPRY Yearly EPS VS EstimatesSPRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SPRY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SPRY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRY Price Earnings VS Forward Price EarningsSPRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRY Per share dataSPRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5 2

4.3 Compensation for Growth

A more expensive valuation may be justified as SPRY's earnings are expected to grow with 67.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-269.16%
EPS Next 3Y67.41%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (5/29/2025, 8:14:54 PM)

After market: 15.49 0 (0%)

15.49

+0.64 (+4.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners66.89%
Inst Owner ChangeN/A
Ins Owners18.28%
Ins Owner Change-0.36%
Market Cap1.52B
Analysts88.33
Price Target32.23 (108.07%)
Short Float %24.88%
Short Ratio9.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)222.08%
Min EPS beat(2)1.02%
Max EPS beat(2)443.14%
EPS beat(4)2
Avg EPS beat(4)100.5%
Min EPS beat(4)-32.93%
Max EPS beat(4)443.14%
EPS beat(8)5
Avg EPS beat(8)58.43%
EPS beat(12)7
Avg EPS beat(12)92.08%
EPS beat(16)9
Avg EPS beat(16)66.26%
Revenue beat(2)2
Avg Revenue beat(2)220.56%
Min Revenue beat(2)4.48%
Max Revenue beat(2)436.64%
Revenue beat(4)3
Avg Revenue beat(4)160.69%
Min Revenue beat(4)-50.98%
Max Revenue beat(4)436.64%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-2.77%
EPS NQ rev (1m)-6.15%
EPS NQ rev (3m)-127.16%
EPS NY rev (1m)-3.56%
EPS NY rev (3m)-298.58%
Revenue NQ rev (1m)1.11%
Revenue NQ rev (3m)-8.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.66
P/FCF N/A
P/OCF N/A
P/B 6.64
P/tB 6.86
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0.99
BVpS2.33
TBVpS2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.78%
ROE -6.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 90.89%
FCFM N/A
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 164.08%
Cap/Sales 0.59%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11
Quick Ratio 10.74
Altman-Z 9.65
F-Score4
WACC9.53%
ROIC/WACCN/A
Cap/Depr(3y)338.3%
Cap/Depr(5y)266.86%
Cap/Sales(3y)199.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-218.18%
EPS Next Y-2966.2%
EPS Next 2Y-269.16%
EPS Next 3Y67.41%
EPS Next 5Y88.12%
Revenue 1Y (TTM)971120%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year380.02%
Revenue Next 2Y240.61%
Revenue Next 3Y163.51%
Revenue Next 5Y104.65%
EBIT growth 1Y56.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-119.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.49%
OCF growth 3YN/A
OCF growth 5YN/A